Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

Bispecific antibody

Screenshot of first page of the PLSP
16th Apr 2026

A plain language summary on the ELM-2 study: odronextamab for relapsed/refractory follicular lymphoma

25th Feb 2026

Managing specific adverse effects of teclistamab in multiple myeloma patients: a plain language summary

A screenshot of the PLSP article
19th Sep 2025

A plain language summary of the MonumenTAL-1 study: talquetamab for relapsed/ refractory multiple myeloma

This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. A phase 1 study is an early clinical trial where researchers evaluate how safe a medicine is at different doses in a small number of people. In the MonumenTAL-1 study, researchers looked at a new medicine under development called talquetamab, for people living with multiple myeloma (a type of blood cancer) who did not respond (refractory), stopped responding (relapsed) or who had difficulty dealing with their previous treatments.
9th Aug 2023

The MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma- a plain language summary

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy